Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.227
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 5, August, p. 825–828

doi: 10.17219/acem/61100

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Usefulness of a new anthropometric indicator – VAI (Visceral Adiposity Index) in the evaluation of metabolic and hormonal disorders in women with polycystic ovary syndrome

Anna Brończyk-Puzoń1,A,D,E, Paweł Jagielski2,B,C,E, Karolina Kulik-Kupka1,D,E, Aneta Koszowska1,D,E, Justyna Nowak1,D,E, Barbara Zubelewicz-Szkodzińska1,A,E,F

1 Department of Nutrition-Related Diseases Prevention, School of Public Health in Bytom, Medical University of Silesia, Katowice, Poland

2 Human Nutrition Department, Faculty of Health Science, Jagiellonian University Medical College, Kraków, Poland

Abstract

Background. Visceral adiposity index (VAI) is a new anthropometric indicator that makes it possible to define the risk of obesity-related cardiometabolic complications even before the diagnosis of metabolic syndrome.
Objectives. Evaluating the usefulness of VAI in order to differentiate metabolically unhealthy women (MU-PCOS) and defining the usefulness of this index in everyday practice.
Material and Methods. A prospective study was conducted among 43 women who met the Rotterdam criteria for diagnosing polycystic ovarian syndrome. Body composition was measured using bioelectrical impedance analysis. Statistical analysis was performed using STATISTICA v. 10 and relevant statistical tests. The adopted significance level was p = 0.05.
Results. Based on the study results, a significant positive correlation was found between the value of VAI and the concentration of insulin (r = 0.33; p < 0.01), HOMA index (r = 0.46; p < 0.01) and FAI (r = 0.54; p < 0.01). It was also shown that there is a significant negative correlation between VAI and the concentration of SHBG (r = -0.53; p < 0.01) and HDL cholesterol (r = -0.88; p < 0.01). In the group of metabolically unhealthy women, the research showed a significantly higher value of free testosterone, SHGB, DHEAS and FAI (p < 0.05).
Conclusion. Visceral adiposity index makes it possible to introduce early prevention of metabolic disorders (including cardiometabolic disorders), as well as to evaluate the increase of hyperandrogenemia in women with polycystic ovary syndrome. The use of the cut-off point of VAI = 1.675 is a simple way to evaluate women with MU-PCOS.

Key words

polycystic ovarian syndrome, visceral adiposity index, metabolic disorders

References (8)

  1. Amato MC, Giordano C. Visceral Adiposity Index: An indicator of adipose tissue dysfunction. Int J Endocrinol. 2014, ID 730827, 7. doi: 10.1155/2014/730827.
  2. Oh JY, Sung YA, Lee HJ. The visceral adiposity index as a predictor of insulin resistance in young women with polycystic ovary syndrome. Obesity. 2013;21:1690–1694. doi:10.1002/oby.20096.
  3. Amato MC, Giordano C, Galia M, et al. AlkaMeSy Study Group: Visceral adiposity index: A reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33:920–922.
  4. Ranasinha S, Joham AE, Norman RF, et al. The association between polycystic ovary syndrome (PCOS) and metabolic syndrome: A statistical modelling approach. Clinical Endocrinology. 2015;12830. doi: 10.1111/cen.12830.
  5. Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocrine Reviews. 1997;18:774–800.
  6. Amato MC, Guarnotta V, Forti D, Donatelli M, Dolcimascolo S, Giordano C. Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): A comparative analysis of four simple methods useful for metabolic assessment. Human Reproduction. 2013;28:1919–1928.
  7. Androulakis II, Kandaraki E, Christakou C, et al. Visceral adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2014;81:426–431.
  8. Amato MC, Magistro A, Gambino G, Vesco R, Giordano C. Visceral adiposity index and DHEAS are useful markers of diabetes risk in women with polycystic ovary syndrome. Eur J Endocrinol. 2015;172:79–88.